Free Trial

BridgeBio Oncology Therapeutics (BBOT) Stock Price, News & Analysis

BridgeBio Oncology Therapeutics logo
$8.82 +0.29 (+3.40%)
As of 03:14 PM Eastern
This is a fair market value price provided by Massive. Learn more.

About BridgeBio Oncology Therapeutics Stock (NASDAQ:BBOT)

Advanced

Key Stats

Today's Range
$8.41
$8.79
50-Day Range
$7.66
$9.48
52-Week Range
$7.60
$14.87
Volume
45,284 shs
Average Volume
345,860 shs
Market Capitalization
$706.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Moderate Buy

Company Overview

BridgeBio Oncology Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
46th Percentile Overall Score

BBOT MarketRank™: 

BridgeBio Oncology Therapeutics scored higher than 46% of companies evaluated by MarketBeat, and ranked 53rd out of 97 stocks in the financial services sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BridgeBio Oncology Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on no strong buy ratings, 4 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    BridgeBio Oncology Therapeutics has a consensus price target of $25.00, representing about 188.5% upside from its current price of $8.67.

  • Amount of Analyst Coverage

    BridgeBio Oncology Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about BridgeBio Oncology Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for BridgeBio Oncology Therapeutics are expected to decrease in the coming year, from ($2.18) to ($2.21) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BridgeBio Oncology Therapeutics is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BridgeBio Oncology Therapeutics is -4.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    BridgeBio Oncology Therapeutics has a P/B Ratio of 1.86. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    5.41% of the float of BridgeBio Oncology Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    BridgeBio Oncology Therapeutics has a short interest ratio ("days to cover") of 10.12, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in BridgeBio Oncology Therapeutics has recently decreased by 1.37%, indicating that investor sentiment is improving.
  • Dividend Yield

    BridgeBio Oncology Therapeutics does not currently pay a dividend.

  • Dividend Growth

    BridgeBio Oncology Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    BridgeBio Oncology Therapeutics has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.73 average news sentiment score of Financial Services companies.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for BridgeBio Oncology Therapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, BridgeBio Oncology Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    24.40% of the stock of BridgeBio Oncology Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    54.89% of the stock of BridgeBio Oncology Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about BridgeBio Oncology Therapeutics' insider trading history.
Receive BBOT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BridgeBio Oncology Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BBOT Stock News Headlines

Why SMX Could Be a High-Upside Small-Cap Stock
SMX (Security Matters) Public Limited is developing molecular-level markers embedded into plastics, fuels, metals, textiles, and industrial commodities to give physical materials a digital identity. Its Digital Material Passport technology targets verification of origin, recycled content, and lifecycle data across global supply chains - a market growing more compliance-driven by the day. As governments tighten recycled-content reporting standards, SMX is positioning itself inside one of the decade's most consequential industrial shifts.tc pixel
See More Headlines

BBOT Stock Analysis - Frequently Asked Questions

BridgeBio Oncology Therapeutics' stock was trading at $11.50 at the beginning of the year. Since then, BBOT stock has decreased by 24.7% and is now trading at $8.6650.

BridgeBio Oncology Therapeutics, Inc (NASDAQ:BBOT) announced its quarterly earnings results on Tuesday, May, 12th. The company reported ($526.11) EPS for the quarter.

Top institutional shareholders of BridgeBio Oncology Therapeutics include Octagon Capital Advisors LP (0.90%), Granahan Investment Management LLC (0.29%), Renaissance Technologies LLC (0.13%) and Avidity Partners Management LP (0.05%).

Shares of BBOT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/12/2026
Today
5/28/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Investment Offices
Sub-Industry
Trading
Current Symbol
NASDAQ:BBOT
CIK
1869105
Fax
N/A
Employees
N/A
Year Founded
2025

Price Target and Rating

High Price Target
$29.00
Low Price Target
$23.00
Potential Upside/Downside
+188.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
6.16
Quick Ratio
6.16

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.65 per share
Price / Book
1.86

Miscellaneous

Outstanding Shares
80,110,000
Free Float
60,561,000
Market Cap
$694.15 million
Optionable
N/A
Beta
0.22

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply click the link below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:BBOT) was last updated on 5/28/2026 by MarketBeat.com Staff.
From Our Partners